A RANDOMIZED PHASE II TRIAL OF EPOCH (AIDS)

EPOCH 的随机 II 期试验（艾滋病）

• 批准号: 7603909
• 负责人: ALEXANDRA M LEVINE
• 金额: $ 24.41万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7603909
• 关键词: AIDS Malignancy Consortium; AIDS-Related Lymphoma; B-Cell Lymphomas; Computer Retrieval of Information on Scientific Projects Database; Cyclophosphamide; Cyclophosphamide/Doxorubicin/Etoposide/Prednisone/Vincristine; Disease remission; Etoposide/Prednisone; Funding; Grant; In complete remission; Institution; Kyocristine; Maintenance Therapy; Monoclonal Antibodies; National Cancer Institute; Newly Diagnosed; Patients; Phase; Purpose; Randomized; Rate; Research; Research Personnel; Resources; Source; Treatment Protocols; United States National Institutes of Health; chemotherapy; improved; pilot trial; rituximab

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. In pilot trials conducted at the National Cancer Institute, infusional chemotherapy with EPOCH (etoposide, prednisone, Oncovin, cyclophosphamide, hydroxydaunomycin (doroxubicin) is associated with durable complete remission in over 75% of patients with newly diagnosed AIDS-related lymphomas. The purpose of this trial is to determine if the addition of the monoclonal antibody rituximab to the EPOCH regimen will improve the complete remission rate and its durability in the treatment of newly diagnosed patients with AIDS-related B-cell lymphomas. In this multi-center trial sponsored by the NCI-AIDS Malignancy consortium, 70 patients will be randomized to receive either rituximab either given concurrently with ePOCH or as maintenance therapy.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 在美国国家癌症研究所进行的试点试验中，EPOCH（依托泊苷、强的松、Oncovin、环磷酰胺、羟基道诺霉素（多柔比星））输注化疗与超过 75% 的新诊断艾滋病相关淋巴瘤患者的持久完全缓解相关。该试验的目的是确定添加单克隆抗体是否有效 EPOCH方案中加入利妥昔单抗将提高新诊断的艾滋病相关B细胞淋巴瘤患者的完全缓解率及其持久性。在这项由 NCI-AIDS 恶性肿瘤联盟赞助的多中心试验中，70 名患者将被随机分配接受利妥昔单抗治疗，或者与 ePOCH 同时给予或作为维持治疗。